US company C R Bard has acquired Angiomed, a German manufacturer of specialty health care products. Terms of the deal were not disclosed. Bard will consolidate its current Germany operations, which are based in Munich, at Angiomed's headquarters in Karlsruhe, where nearly 400 Angiomed employees are based.
Angiomed had 1993 revenues of $40 million, with most of its sales generated in Germany. Bard reported 1993 revenues of $970.8 million and has said it expects some decline in earnings per share for the fourth quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze